348 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
2 Frustrating Flops, Plus Welcome to the Wrinkle Wars https://www.fool.com/investing/2019/02/21/2-frustrating-flops-plus-welcome-to-the-wrinkle-wa.aspx?source=iedfolrf0000001 Feb 21, 2019 - Disappointing data from Gilead Sciences and Sangamo weigh on investors, while one tiny stock challenges Allergan.
Allergan Responds to Investor's Call for CEO/Chair Role Split http://www.zacks.com/stock/news/355578/allergan-responds-to-investors-call-for-ceo-chair-role-split?cid=CS-ZC-FT-355578 Feb 20, 2019 - Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
Companies Roll Out Gunshot Detectors at the Office https://www.wsj.com/articles/companies-roll-out-gunshot-detectors-at-the-office-11550575801?mod=rss_Technology Feb 19, 2019 - Corporate executives worried about workplace shootings are quietly installing gunfire-detection systems in U.S. offices and factories. Most don’t tell employees what the sensors are, for fear of alarming them.
Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2018 http://www.gurufocus.com/news/817582/allergan-plc-agn-files-10k-for-the-fiscal-year-ended-on-december-31-2018 Feb 15, 2019 - Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2018, Stocks: AGN, release date:Feb 15, 2019
Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down http://www.zacks.com/stock/news/354559/teva-teva-q4-earnings-miss19-view-weak-shares-down?cid=CS-ZC-FT-354559 Feb 14, 2019 - Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.
Flip the Script: Drugmakers Blame Middlemen for Price Increases https://www.wsj.com/articles/flip-the-script-drugmakers-blame-middlemen-for-price-hikes-11549364401?mod=pls_whats_news_us_business_f Feb 05, 2019 - Under pressure over rising drug prices, pharmaceutical companies are pushing a new defense: They’re not raising prices to make money or to cover research costs, but rather to pay a cut to middlemen in the supply chain.
Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines http://www.zacks.com/stock/news/352006/allergan-stock-falls-as-fda-oks-botox-rival-for-frown-lines?cid=CS-ZC-FT-352006 Feb 05, 2019 - Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
Allergan (AGN) Q4 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2019/01/29/allergan-agn-q4-2018-earnings-conference-call-tran.aspx?source=iedfolrf0000001 Jan 29, 2019 - AGN earnings call for the period ending December 31, 2018.
Allergan Plc (AGN) CEO Brent Saunders on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4236451-allergan-plc-agn-ceo-brent-saunders-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Jan 29, 2019 - Allergan Plc (NYSE:AGN) Q4 2018 Earnings Conference Call January 29, 2019 08:30 AM ET Company Participants Manisha Narasimhan - Investor Relations Brenton L. Saunders - Chairman, President & CEO W
Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid http://www.zacks.com/stock/news/350482/allergan-agn-q4-earnings-beat-estimates-2019-view-tepid?cid=CS-ZC-FT-350482 Jan 29, 2019 - Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.

Pages: 12345678910...35

<<<Page 5>